Lupin's Luforbec - First Generic Alternative To Fostair's Inhaler: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Lupin Ltd. received U.K. marketing authorisation for Luforbec 100/6 mg pressurised metered-dose inhalers from Medicines and Healthcare products Regulatory Agency, which is a first branded generic alternative of Fostair 100/6 mg pMDI, to treat Asthma and chronic obstructive pulmonary disease patients.
With right pricing strategy, the company may offer NHS (the U.K. agency to procure medicines for government hospitals) a cost efficient option to replace Fostair in its procurement policy, as it incurred £179 million (12 months ending, February-2021) for these patients.
Upcoming launch of Luforbec will be in line with the company strategy to expand anti-asthma/COPD portfolio across key markets.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.